drugset / Trial / NCT01549223
Oxytocin And Uterotonic Agent Use For Cesarean Delivery
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dosing regimen, during elective cesarean delivery will: 1\. Reduce the overall amount of oxytocin and other uterotonic agents used to obtain satisfactory uterine tone. Secondary outcomes to be evaluated will be: 1. Reduce the side effects associated with uterotonic drug use 2. Reduce the time to establishment and maintenance of adequate uterine tone
Timeline
- Start
- 2011-04
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboprost Tromethamine | Unknown | 0.25 mg | Intramuscular |
| Subject | Methylergonovine | Small molecule | 0.2 mg | Intramuscular |
| Subject | Misoprostol | Other / unclassified | 600 ug | Other |
| Comparator | Oxytocin | Peptide | 3 iu | Intravenous |
| Comparator | Oxytocin | Peptide | 30 iu | Intravenous |